Duijm Lucien E M, Groenewoud Johanna H, de Koning Harry J, Coebergh Jan Willem, van Beek Mike, Hooijen Marianne J H H, van de Poll-Franse Lonneke V
Department of Radiology, Catharina Hospital, Eindhoven, The Netherlands.
Eur J Cancer. 2009 Mar;45(5):774-81. doi: 10.1016/j.ejca.2008.10.020. Epub 2008 Dec 4.
To determine the frequency, pathology and causes of a delay in cancer diagnosis in women recalled for suspicious screening mammography.
We included all 290,943 screening mammograms of women aged 50-75 years, who underwent biennial screening mammography between 1st January 1995 and 1st January 2006. During a follow-up period of at least 2 years, clinical data, breast imaging reports, biopsy results and breast surgery reports were collected of all 3513 women with a positive screening result. Tumour stages of breast cancers with a diagnostic delay (defined as breast cancer confirmation more than 3 months following a positive mammography screen) were compared with those of cancers diagnosed within 3 months following referral and with interval cancers.
A diagnostic delay occurred in 97 (6.5%) of 1503 screen-detected cancers. These 97 false-negative assessments comprised significantly more ductal cancers in situ (26.8%) than did cancers with an adequate assessment after recall (15.5%, p=0.004) or interval cancers (3.7%, p<0.001). Compared with interval cancers, cancers with a false-negative assessment had a more favourable tumour size (T1a-c, 87.3% versus T1a-c, 46.4%; p<0.001) and showed significantly fewer cases with axillary lymph node metastases (22.5% versus 48.2%; p<0.001). Between hospitals having performed the workup of at least 500 referred women each, the percentage of women with a false-negative assessment varied from 5.0% to 9.1% (p=0.03). In these hospitals, improper classification of lesions at diagnostic mammography comprised 64.4% of false-negative assessments.
We found that 6.5% of recalled women experienced a delay in breast cancer diagnosis, with significant performance variations between hospitals.
确定因乳腺钼靶筛查结果可疑而被召回的女性癌症诊断延迟的频率、病理及原因。
纳入1995年1月1日至2006年1月1日期间接受两年一次乳腺钼靶筛查的所有50 - 75岁女性的290,943份筛查钼靶影像。在至少2年的随访期内,收集了所有3513名筛查结果阳性女性的临床资料、乳腺影像报告、活检结果及乳腺手术报告。将诊断延迟(定义为钼靶筛查阳性后超过3个月确诊乳腺癌)的乳腺癌肿瘤分期与转诊后3个月内确诊的癌症及间期癌的肿瘤分期进行比较。
1503例筛查发现的癌症中有97例(6.5%)出现诊断延迟。这97例假阴性评估中导管原位癌的比例(26.8%)显著高于召回后评估充分的癌症(15.5%,p = 0.004)或间期癌(3.7%,p < 0.001)。与间期癌相比,假阴性评估的癌症肿瘤大小更有利(T1a - c,87.3% 对 T1a - c,46.4%;p < 0.001),腋窝淋巴结转移的病例明显更少(22.5% 对 48.2%;p < 0.001)。在每家至少对500名转诊女性进行检查的医院中,假阴性评估女性的比例在5.0%至9.1%之间(p = 0.03)。在这些医院中,诊断性乳腺钼靶检查时病变分类不当占假阴性评估的64.4%。
我们发现6.5%被召回的女性乳腺癌诊断出现延迟,不同医院之间的表现存在显著差异。